About Castle Biosciences, Inc.
https://castlebiosciences.comCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
CEO
Derek J. Maetzold
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.19M
Value:$130.05M
BLACKROCK INC.
Shares:3.04M
Value:$124.14M
VANGUARD GROUP INC
Shares:2.17M
Value:$88.57M
Summary
Showing Top 3 of 201
About Castle Biosciences, Inc.
https://castlebiosciences.comCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $83.04M ▼ | $71.14M ▼ | $-501K ▼ | -0.6% ▼ | $-0.02 ▼ | $5.25M ▲ |
| Q2-2025 | $86.19M ▼ | $72.81M ▼ | $4.52M ▲ | 5.25% ▲ | $0.16 ▲ | $3.29M ▼ |
| Q1-2025 | $87.99M ▲ | $99.53M ▲ | $-25.85M ▼ | -29.38% ▼ | $-0.9 ▼ | $3.51M ▼ |
| Q4-2024 | $86.31M ▲ | $66.08M ▲ | $9.59M ▲ | 11.11% ▲ | $0.34 ▲ | $13.74M ▲ |
| Q3-2024 | $85.78M | $65.09M | $2.27M | 2.65% | $0.08 | $12.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $287.54M ▲ | $562.79M ▲ | $95.74M ▲ | $467.05M ▲ |
| Q2-2025 | $275.93M ▲ | $544.73M ▲ | $89.35M ▲ | $455.38M ▲ |
| Q1-2025 | $275.15M ▼ | $501.71M ▼ | $61.41M ▼ | $440.31M ▼ |
| Q4-2024 | $293.13M ▲ | $531.24M ▲ | $75.4M ▲ | $455.83M ▲ |
| Q3-2024 | $279.79M | $514.57M | $73.51M | $441.06M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-501K ▼ | $22.63M ▲ | $-18.39M ▲ | $-919K ▼ | $3.32M ▲ | $7.8M ▼ |
| Q2-2025 | $4.52M ▲ | $20.82M ▲ | $-28.38M ▼ | $101K ▲ | $-7.46M ▲ | $11.56M ▲ |
| Q1-2025 | $-25.85M ▼ | $-6.04M ▼ | $-22.43M ▼ | $-1.55M ▲ | $-30.02M ▼ | $-10.78M ▼ |
| Q4-2024 | $9.59M ▲ | $24.36M ▲ | $5.77M ▲ | $-5.38M ▼ | $24.75M ▲ | $16.8M ▼ |
| Q3-2024 | $2.27M | $23.34M | $-14.79M | $838K | $9.39M | $16.96M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Dermatologic | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ | $50.00M ▼ |
CEO
Derek J. Maetzold
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 143
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.19M
Value:$130.05M
BLACKROCK INC.
Shares:3.04M
Value:$124.14M
VANGUARD GROUP INC
Shares:2.17M
Value:$88.57M
Summary
Showing Top 3 of 201